MX2023004955A - Compuestos de aminotiazol deuterados como compuestos antiviricos. - Google Patents
Compuestos de aminotiazol deuterados como compuestos antiviricos.Info
- Publication number
- MX2023004955A MX2023004955A MX2023004955A MX2023004955A MX2023004955A MX 2023004955 A MX2023004955 A MX 2023004955A MX 2023004955 A MX2023004955 A MX 2023004955A MX 2023004955 A MX2023004955 A MX 2023004955A MX 2023004955 A MX2023004955 A MX 2023004955A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- deuterated
- aminothiazole
- antiviral
- antiviral compounds
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20204545 | 2020-10-29 | ||
| PCT/EP2021/080023 WO2022090409A1 (en) | 2020-10-29 | 2021-10-28 | Deuterated aminothiazole compounds as antiviral compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004955A true MX2023004955A (es) | 2023-05-17 |
Family
ID=73037895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004955A MX2023004955A (es) | 2020-10-29 | 2021-10-28 | Compuestos de aminotiazol deuterados como compuestos antiviricos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12552756B2 (enExample) |
| EP (1) | EP4237414A1 (enExample) |
| JP (1) | JP2023552274A (enExample) |
| KR (1) | KR20230131177A (enExample) |
| CN (1) | CN116783171A (enExample) |
| AU (1) | AU2021367976A1 (enExample) |
| CA (1) | CA3196645A1 (enExample) |
| MX (1) | MX2023004955A (enExample) |
| WO (1) | WO2022090409A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4466255A1 (en) | 2022-01-17 | 2024-11-27 | Innovative Molecules GmbH | Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof |
| IL325911A (en) | 2023-07-17 | 2026-03-01 | Innovative Molecules Gmbh | Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds |
| WO2026078039A1 (en) | 2024-10-09 | 2026-04-16 | Innovative Molecules Gmbh | Oral administration forms of antiviral helicase-primase inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| GEP20207128B (en) * | 2016-04-06 | 2020-07-10 | Molecules Gm Innovative | Aminothiazole derivatives useful as antiviral agents |
| MX2020003369A (es) * | 2017-10-05 | 2020-07-29 | Innovative Molecules Gmbh | Enantiomeros de tiazoles sustituidos como compuestos antivirales. |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
-
2021
- 2021-10-28 KR KR1020237017885A patent/KR20230131177A/ko active Pending
- 2021-10-28 US US18/034,099 patent/US12552756B2/en active Active
- 2021-10-28 CA CA3196645A patent/CA3196645A1/en active Pending
- 2021-10-28 AU AU2021367976A patent/AU2021367976A1/en active Pending
- 2021-10-28 WO PCT/EP2021/080023 patent/WO2022090409A1/en not_active Ceased
- 2021-10-28 JP JP2023526237A patent/JP2023552274A/ja active Pending
- 2021-10-28 EP EP21802293.7A patent/EP4237414A1/en active Pending
- 2021-10-28 CN CN202180088642.XA patent/CN116783171A/zh active Pending
- 2021-10-28 MX MX2023004955A patent/MX2023004955A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116783171A (zh) | 2023-09-19 |
| AU2021367976A9 (en) | 2025-03-13 |
| EP4237414A1 (en) | 2023-09-06 |
| KR20230131177A (ko) | 2023-09-12 |
| US20230391738A1 (en) | 2023-12-07 |
| WO2022090409A1 (en) | 2022-05-05 |
| US12552756B2 (en) | 2026-02-17 |
| AU2021367976A1 (en) | 2023-06-08 |
| JP2023552274A (ja) | 2023-12-15 |
| CA3196645A1 (en) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002695A1 (es) | Péptidos macrocíclicos contra actinetobacter baumannii | |
| MX375099B (es) | Derivados de aminotiazol útiles como agentes antivíricos. | |
| CO2021012579A2 (es) | Compuestos útiles en la terapia del vih | |
| BR112022002496A2 (pt) | Compostos deuterados para uso no tratamento de câncer | |
| MX2023004955A (es) | Compuestos de aminotiazol deuterados como compuestos antiviricos. | |
| PH12018500904A1 (en) | Peptide macrocycles against acinetobacter baumannii | |
| UY35263A (es) | Compuestos terapéuticos | |
| UY37997A (es) | Agentes antivirales contra la hepatitis b | |
| CO6470845A2 (es) | Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales | |
| MX2018005890A (es) | Composiciones para tratar atrofia muscular espinal. | |
| BR112015004113A2 (pt) | 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b | |
| BR112017020837A2 (pt) | compostos de carbamoilpiridona policíclicos e seu uso farmacêutico | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| BR112014006559A2 (pt) | derivados do ácido betulínico com atividade antiviral | |
| BR112023012947A2 (pt) | Inibidores de lrrk2 | |
| CL2020003248A1 (es) | Derivados de tetrahidrotienopiridina n-sustituidos y sus usos | |
| CL2017002498A1 (es) | Piridopirimidinonas y su uso como modulares del receptor nmda | |
| MX2019011220A (es) | Compuesto de pirrolopiridina novedoso, metodo de preparacion del mismo y uso del mismo. | |
| BR112022010181A2 (pt) | Composto tri-heterocíclico como inibidor de jak e uso do mesmo | |
| CR20180615A (es) | Nuevos derivados de [1,2,3]triazol[4,5-d]pirimidina | |
| MX2021012544A (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales. | |
| MY197518A (en) | Preventive and/or therapeutic agent of immune disease | |
| BR112023010200A2 (pt) | Inibidores enzimáticos | |
| CO2022008835A2 (es) | Agonistas del tlr7 | |
| BR112021019589A2 (pt) | Derivados de isocromenos como inibidores de fosfoinositídeo 3-cinases |